Skye Bioscience, Common Stock Performance
| SKYE Stock | USD 2.85 0.01 0.35% |
The entity has a beta of 0.89, which indicates possible diversification benefits within a given portfolio. Skye Bioscience, returns are very sensitive to returns on the market. As the market goes up or down, Skye Bioscience, is expected to follow. At this point, Skye Bioscience, Common has a negative expected return of -0.18%. Please make sure to validate Skye Bioscience,'s total risk alpha, as well as the relationship between the skewness and day median price , to decide if Skye Bioscience, Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Skye Bioscience, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (4.98) | Five Day Return (12.80) | Year To Date Return 5.15 | Ten Year Return (99.87) | All Time Return (99.89) |
Last Split Factor 1:250 | Last Split Date 2023-09-08 |
1 | Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3 | 10/28/2024 |
2 | Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3 | 11/01/2024 |
3 | Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights | 11/07/2024 |
4 | Skye Bioscience Surpasses 50 percent Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor | 11/14/2024 |
5 | Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3 | 11/15/2024 |
6 | Disposition of 86244 shares by Grayson Paul A. of Skye Bioscience, at 4.99 subject to Rule 16b-3 | 11/18/2024 |
7 | Skye Bioscience chief development officer sells shares worth 97,721 | 11/20/2024 |
8 | British Design Firm Forecasts 2025 Color Trends | 11/21/2024 |
9 | Callous coward Finlay MacDonald jailed for life after murdering his brother-in-law | 11/29/2024 |
10 | Insider Trading | 12/09/2024 |
11 | Skye Bioscience to Present at J.P. Morgan Healthcare Conference | 12/19/2024 |
| Begin Period Cash Flow | 1.2 M | |
| Free Cash Flow | -14 M |
Skye |
Skye Bioscience, Relative Risk vs. Return Landscape
If you would invest 349.00 in Skye Bioscience, Common on September 21, 2024 and sell it today you would lose (63.00) from holding Skye Bioscience, Common or give up 18.05% of portfolio value over 90 days. Skye Bioscience, Common is currently does not generate positive expected returns and assumes 5.2473% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Skye, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Skye Bioscience, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Skye Bioscience,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Skye Bioscience, Common, and traders can use it to determine the average amount a Skye Bioscience,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0336
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SKYE |
Estimated Market Risk
| 5.25 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Skye Bioscience, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Skye Bioscience, by adding Skye Bioscience, to a well-diversified portfolio.
Skye Bioscience, Fundamentals Growth
Skye Stock prices reflect investors' perceptions of the future prospects and financial health of Skye Bioscience,, and Skye Bioscience, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Skye Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 19.55 M | ||||
| Shares Outstanding | 30.34 M | ||||
| Price To Book | 1.14 X | ||||
| EBITDA | (13.55 M) | ||||
| Net Income | (37.64 M) | ||||
| Cash And Equivalents | 2.93 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (13.95 M) | ||||
| Earnings Per Share | (3.60) X | ||||
| Market Capitalization | 163.52 M | ||||
| Total Asset | 11.94 M | ||||
| Retained Earnings | (104.38 M) | ||||
| Working Capital | (2.25 M) | ||||
About Skye Bioscience, Performance
By analyzing Skye Bioscience,'s fundamental ratios, stakeholders can gain valuable insights into Skye Bioscience,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Skye Bioscience, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Skye Bioscience, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -2.2 K | -2.1 K | |
| Return On Tangible Assets | (3.15) | (3.31) | |
| Return On Capital Employed | 6.97 | 3.58 | |
| Return On Assets | (3.15) | (3.31) | |
| Return On Equity | 17.66 | 18.54 |
Things to note about Skye Bioscience, Common performance evaluation
Checking the ongoing alerts about Skye Bioscience, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Skye Bioscience, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Skye Bioscience, generated a negative expected return over the last 90 days | |
| Skye Bioscience, has high historical volatility and very poor performance | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Skye Bioscience to Present at J.P. Morgan Healthcare Conference |
- Analyzing Skye Bioscience,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Skye Bioscience,'s stock is overvalued or undervalued compared to its peers.
- Examining Skye Bioscience,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Skye Bioscience,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Skye Bioscience,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Skye Bioscience,'s stock. These opinions can provide insight into Skye Bioscience,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Skye Stock analysis
When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world |